BACKGROUND Leishmaniasis is a complex disease which presents as visceral, cutaneous and mucocutaneous forms. The current treatment options for this infection are very limited and the immunological state of the host appears to play an important role in the efficacy of the treatment. Immunostimulation through immune response activating agents such as Imiquimod is another rational approach for thi...

Leishmaniasis is a neglected and endemic disease that affects poorest population mainly in developing countries. A lack of adequate and definitive chemotherapeutic agents to fight against this infection has led to the investigation of numerous compounds. The aim of this study was to investigate in vitro activity of boldine against Leishmania amazonensis murine cell infection. Boldine ((S)-2,9-d...

BACKGROUND Leishmaniasis is a parasitic infection that may lead to a variety of manifestations. In Iran, cutaneous leishmaniasis (CL) has a high prevalence. There are many treatment modalities for CL. The use of oral terbinafine in the treatment of CL has recently been considered. The aim of this study was to compare combination of oral terbinafine plus cryotherapy versus systemic meglumine ant...

Background. Topical treatment of cutaneous leishmaniasis is an attractive alternative avoiding toxicities of parenteral therapy while being administered through a simple painless route. Recently liposomal formulations of amphotericin B have been increasingly used in the treatment of several types of leishmaniasis. Aims. The efficacy of a topical liposomal amphotericin B formulation was compared...

The authors report a case of a male patient from Bacabal, MA with diffuse cutaneous leishmaniasis (DCL), for at least nine years, with 168 lesions on his body. These were tumour-like nodules with some ulceration. He used pentavalent antimonial (glucantime) and an association of gamma interferon plus glucantime with improvement of the lesions but relapsed later. Recently, pentamidine isethionate...

Background: Cutaneous leishmaniasis (CL) is a parasitic disease caused by leishmania species. An ideal treatment for CL has not found yet. Objectives: To evaluate the efficacy of cryotherapy alone and combined with intralesional glucantime injection in the treatment of papulonodular CL. Patients and Methods: 300 patients with CL were randomly assigned to two treatment groups in this clini...

Background and aim: Complications and resistance to pentavalent antimonial agents in cutaneous leishmaniasis, exhibit the need for effective alternative drugs. The aim of this study was to compare the efficacy of oral azithromycin with systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis. Materials and Methods: Forty-seven patients with cutaneous leishmaniasis...

Background and aim: Pentavalent antimony compounds are the first line treatment for cutaneous leishmaniasis. Clinical resistance to pentavalent antimony in the form of meglumine antimoniate (Glucantime) has been recognized as a problem in leishmaniasis. Herein, clinical response to Glucantime were studied in patients suffered from cutaneous leishmaniasis.Materials and Methods: In a cross-sectio...

toxicity and drug resistance against pentavalent antimonials, medications of choice in treatment of leishmaniasis for more than 5 decades, have become important subjects globally. this study was a randomized, open labeled trial that was designed to determine efficacy and safety of imod as a novel herbal immunomodulator drug for treatment of canine visceral leishmaniasis (cvl).twenty healthy mon...